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Abstract: Longevity risk constitutes an important risk factor for life insurance companies, and it can be
managed through longevity-linked securities. The market of longevity-linked securities is at present
far from being complete and does not allow finding a unique pricing measure. We propose a method
to estimate the maximum market price of longevity risk depending on the risk margin implicit within
the calculation of the technical provisions as defined by Solvency II. The maximum price of longevity
risk is determined for a survivor forward (S-forward), an agreement between two counterparties to
exchange at maturity a fixed survival-dependent payment for a payment depending on the realized
survival of a given cohort of individuals. The maximum prices determined for the S-forwards can be
used to price other longevity-linked securities, such as q-forwards. The Cairns–Blake–Dowd model is
used to represent the evolution of mortality over time that combined with the information on the risk
margin, enables us to calculate upper limits for the risk-adjusted survival probabilities, the market
price of longevity risk and the S-forward prices. Numerical results can be extended for the pricing of
other longevity-linked securities.
Keywords: longevity risk; S-forwards; pricing; risk margin; Solvency II
1. Introduction
Currently, one of the main risks affecting pension funds and insurance companies selling
annuity products is longevity risk, i.e., the risk to experience unexpected improvements in lifetime
duration. Longevity risk implications are represented by the extension of the average period of
the annuity payment, corresponding to unexpectedly higher actuarial liabilities. In the technical
specifications released by EIOPA (2014a) “Longevity risk is associated with the risk of loss, or of adverse
change in the value of insurance liabilities, resulting from changes in the level, trend, or volatility of
mortality rates, where a decrease in the mortality rate leads to an increase in the value of insurance
liabilities”. According to the report on fifth Quantitative Impact Study EIOPA (2011), in the Solvency
II life underwriting risk module, longevity risk is (together with the lapse risk) the main risk for life
insurance companies.
Longevity risk can be hedged in several ways. One of the most appealing solutions is to transfer
longevity risk to capital markets through the so-called longevity-linked securities, financial contracts
that have payoffs linked to the level of a survivor index of a reference population. Over the past few
years, considerable attention was paid to longevity risk securitization on behalf of major investment
banks, pension funds and reinsurers. Several longevity-linked securities have been proposed in
the literature: e.g., longevity bonds, q -forwards, survivor swaps and longevity caps and floors
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(see, e.g., Blake et al. (2006) for a detailed description), but only some of them were issued in the
market.
One of the main obstacles that slows down the development of a worldwide longevity market is
determining the price of these instruments. The longevity market is currently incomplete and makes it
impossible to estimate a unique market price of longevity risk, i.e., the premium that a life insurer or
pension plan might be willing to pay to release such a risk. Many authors have addressed the question
of how to price longevity-linked securities, but the calibration of the market price of longevity risk
remains an open question (see Bauer et al. (2010) for a review and comparison of different pricing
approaches). Some authors explored the possibility to link the price of longevity-linked securities
to the amount that the insurer should hold to cover unexpected losses. In particular, Börger (2010)
asserts that the risk margin under Solvency II can be considered as the “maximum price” that a life
insurer would be willing to pay to transfer longevity risk via securitization. In the same context,
Stevens et al. (2009) determine the “maximum price” of a portfolio of survivor swaps as the difference
between the buffer (asset value in excess of the best estimate liabilities) sufficient to cover all future
liabilities with a certain probability with and without a survivor swap. The work in Meyricke and
Sherris (2014) analyzes the trade off between the costs and benefits of hedging longevity risk, where
“the benefits arise from reduction in the Solvency Capital Requirement that would otherwise have to
be held against longevity risk under Solvency II”.
Under this approach, we propose a method to estimate the maximum price of longevity risk from
the risk margin for longevity implicit in the market-consistent evaluation of technical provisions under
Solvency II legislation. According to Solvency II, insurance liabilities that cannot be hedged, e.g., the
ones deriving from longevity risk, are calculated as the sum of a best estimate plus a risk margin
(RM), which is the market value of the uncertainty on insurance obligations. The RM is determined
by the cost of capital approach based on future solvency capital requirements (SCR). The overall SCR
is then calculated by aggregating capital requirements from individual risk modules (longevity risk
and other risk factors), using the relevant correlation matrices. As pointed out by Börger (2010),
a shortcoming of the approach to estimating a market price of longevity risk is that the maximum
price an insurer is willing to pay may be different due to diversification effects with other risks than
longevity. Diversification can be achieved by natural hedging, i.e., by combining products that have
negative correlation, in order to lower the insurer’s overall risk exposure. However, the insurer has its
own specific portfolio and tailored natural hedging strategies that would clearly differ from insurer to
insurer. Consequently, since the aim of the paper is to find the maximum price of longevity risk for a
generic insurer, natural hedging between longevity and mortality (as well as other risk diversification
strategies) cannot be included in the model. If the capital associated with longevity, risk was evaluated
in light of the capital allocation of the total diversified SCR; the view on the “maximum price” would
change. Although it is generally correct to take account of diversification effects, the paper focuses on
the situation of an insurer that wishes to hedge a net longevity position considering the SCR for the
stand-alone longevity risk, net of diversification effects accordingly.
The longevity risk can be mitigated and the SCR for longevity risk reduced, if the insurer enters
into a longevity-linked security. If an insurer is completely hedged from longevity risk after entering
a longevity-linked security, SCR for longevity risk reduces to zero, and so does the corresponding RM.
Therefore, the risk margin measures the benefit to the insurer from longevity risk hedging obtained
through securitization. In other words, the insurer is interested in securitization if its cost is less
than the saving of RM that he/she could obtain from its use; otherwise, he/she gives up to cover the
longevity risk and holds the regulatory capital necessary to address it. Therefore, the RM for longevity
risk can be considered an estimation of the maximum price that the insurer would be willing to pay to
transfer longevity risk.
Note that we provide estimates of the maximum acceptable price of longevity risk, without
taking into account the minimum price. From the insurer’s point of view, on which the paper focuses,
there is no minimum price of longevity risk below which he/she would not transfer the risk to the
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capital markets. The minimum price can only be determined from the point of view of the longevity
insurance seller, but if this entity is not an insurance/reinsurance undertaking and therefore not
regulated by Solvency II, a methodological framework based on the RM is not usable to determine the
minimum price. When available, upper and lower bounds for the risk premium specify a “price range
for negotiation between sellers and buyers” (Cui 2008) and “any price within this range can be an
acceptable transaction price” (Barrieu and Loubergé 2013).
The approach we propose could also be applied to insurers subject to other solvency regimes, e.g.,
to those subject to the Swiss Solvency Test that provides a market value margin calculated with the
cost of capital approach (similarly to Solvency II) that would be reduced to zero in the case of perfect
hedging. We will not deal with this aspect here. For further information on the Swiss Solvency Test, the
reader can refer to the Swiss Federal Office of Private Insurance SWISS (2006) and Eling et al. (2008).
However, longevity-linked securities are affected by the counterparty default risk that can
increase their costs and implies a specific capital charge for the insurer entering in the transaction
(see Biffis et al. (2016) for an analysis of counterparty default risk in longevity swaps). The calculation
of the risk margin for counterparty default risk in longevity-linked securities is beyond the scope of
this paper. If the counterparty default risk were introduced, it would reduce the SCR savings achieved
by the longevity risk hedging and would increase the cost of hedging. If such risk is taken into account,
the “maximum price” should be less.
Existing literature (see, e.g., Li and Hardy (2011)) shows that the longevity hedge is affected
by basis risk, the risk caused by the difference between the reference population of the hedging
instrument and the insured population. The presence of basis risk decreases the hedge effectiveness
of the hedging instrument, and a larger solvency capital requirement is necessary to cover future
liabilities. However, in this paper, we do not take into account basis risk, as we assume that the
insurer’s reference population is the same as the longevity-linked instruments.
To determine the maximum price of longevity risk, we consider a survivor forward (S-forward),
an agreement between two counterparties to exchange at maturity a fixed survival-dependent payment
for a payment depending on the realized survival of a given cohort of individuals. An insurer wishing
to hedge longevity risk may enter into a portfolio of S-forwards taking a long position, i.e., assuming
an obligation to pay fixed payments in return for variable payments. The S-forward premium is
measured as the difference between the fixed and the expected value of future cash flows and can be
represented by a spread. We propose a method to determine the maximum spread that the longevity
risk hedger is willing to pay to cover unexpected losses. It is calculated such that, at inception, the
RM of a given insurance contract hedged by the S-forward is equal to the RM of the contract without
longevity hedging, so that the two solutions are indifferent. We conduct the analysis by considering
three different calculation methods of the SCR allowed under the Solvency II project: the standard
formula, the value at risk (VaR) approach and the stressed-trend approach, so that the assessment is
consistent with the measurement of the SCR and RM chosen by the insurance company.
Mortality dynamics are modeled via a stochastic projection model to take into account the
uncertainty in the future evolution of mortality. To find the model that best fits Italian data, we compare
the performances of seven different models. The Cairns–Blake–Dowd model (Cairns et al. 2006a) with
a cohort effect is the model that best fits the data. Our results show that the maximum spread increases
with the starting age of the S-forward underlying cohort, as well as with the maturity, due to the
increasing uncertainty of survival probabilities for older ages and longer time. For example, under
the standard formula approach, the maximum risk premium accepted by insurers for an S-forward
written on a cohort of Italian males aged 65 at the issue of the annuity is 0.3% for five-year maturity
and 15.4% for a 20-year maturity.
We estimate the maximum price of longevity risk according to a risk-neutral pricing framework
that includes a risk adjustment into the real-world probability distribution. In the risk-neutral valuation,
the mortality dynamics is specified under a risk-adjusted measure that is equivalent to the real-world
measure, and the expected cash flows can be discounted to the risk-free rate. Once having defined
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the mortality model under the real-world probability measure, we use the RM approach to calculate
the maximum value of the risk-neutral survival probabilities and find the maximum market price
of longevity risk minimizing the squared errors between this value and the real-world survival
probabilities. In the same pricing framework, the upper limit of the longevity risk market price can
be used to price other and more complex longevity-linked securities, such as survivor swaps and
q-forwards. To determine the longevity risk premium, Milevsky et al. (2005) proposed the Sharpe
ratio approach based on both expected value and the volatility of payments. Under this approach,
the expected return on the longevity-linked securities is equal to the risk-free rate plus the Sharpe ratio
multiplied three times its standard deviation. The work in Milevsky et al. (2006) stated that for the
longevity market, the Sharpe ratio can be set equal to that from the S&P500 index, i.e., 0.25.
In this context, we firstly determine the maximum price of a set of q-forwards through our model
based on the RM approach and then estimate the implied maximum Sharpe ratio that can be considered
acceptable by an annuity provider for hedging longevity risk.
Although the use of RM to price the longevity-linked securities has been suggested in the literature,
the method we propose is original, as it provides an exact measurement of the maximum price of
these hedging instruments, allowing insurers to assess their actual convenience to longevity risk
securitization and thus promoting the longevity market development.
The paper is organized as follows. Section 2 describes the features of S-forwards. In Section 3,
we present the method to determine the maximum price of an S-forward contract from the RM in
the Solvency II framework, as well as the procedure to estimate the corresponding market price of
longevity risk. Section 4 describes the mortality model adopted in the paper and provides the results
of the model fitting applied to the Italian male population. The risk-neutral version of the model
necessary for pricing S-forwards is also shown. Section 5 gives numerical results for the “maximum
price” of S-forwards written on the Italian population for different cohorts and maturities and the
underlying market price of longevity risk. Conclusions are given in Section 6.
2. S-Forwards: Definition and Notation
Consider the situation of an insurer with a portfolio of pure endowments paying a lump sum at
maturity T, if the insured is still alive.
We assume the same sum insured for all of the policyholders. In this regard, where the sums
insured are different, their heterogeneity may affect the riskiness of the insurance portfolio. Actually,
a stronger dispersion in the insured amounts leads to a higher capital requirement due to random
fluctuations in mortality. Otherwise, as pointed out by Pitacco et al. (2009) (see page 317 for further
details), longevity risk is independent of the heterogeneity of the portfolio. Therefore, as our paper
focuses on longevity risk, we do not consider the effect of the heterogeneity of the insured amounts on
the portfolio’s riskiness.
Suppose that he/she decides to transfer the longevity risk arising from this portfolio to the capital
market through a set of S-forwards, as a static hedge. An S-forward is an agreement between two
counterparties to exchange at a fixed maturity T an amount equal to the realized survival probability
of a given population cohort (floating rate payment), in return for a fixed survival probability agreed
at the inception of the contract (fixed rate payment). Among the longevity-linked securities we have
chosen the S-forwards for several reasons: they are certainly very promising instruments thanks to
their lower transactions costs, high flexibility and easiness to be canceled, and they require only the will
of the counterparties to transfer their death exposure without the need of a liquid market. Further, they
involve lower basis risk compared with other derivatives. As stated in the Introduction, we assume
that the insurer’s reference population is the same as the S-forward’s one.
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Consider a cohort of identical policyholders, lx,0, all aged x at initial Time 0. For easiness of
representation, lump sums are fixed to one monetary unit (m.u.). At maturity T, the number of
survivors to age x + T (both realized and expected) is:
lx+T,T = lx,0 · T px,0 (realized) (1a)
lˆx+T,T = EP (lx+T,T) = lx,0 · T pˆx,0 (expected) (1b)
where T px,0 is the survival rate of an individual aged x at Time 0 to be alive at age x + T, EP is the
expectation operator associated with real world probability measure P and T pˆx,0 = EP (T px,0). If the
difference between the realized and the expected survivor at time T is positive, i.e., lx+T,T − lˆx+T,T > 0,
the insurer experiences a portfolio loss at time T.
Let (1+ pi)lˆx+T,T be the fixed leg of the S-forward at time T, where pi is the fixed proportional
risk premium required by investors to take on longevity risk and lx+T,T the floating leg. At payment
date T, the cash-flow is equal to the difference between the fixed leg and the floating leg (Figure 1).
Figure 1. S-forward cash flows.
As observed in the Introduction, the pricing of longevity-linked securities is far from being trivial.
The existing literature on this topic is quite extensive, and there is a lively debate concerning the
performance of different approaches for pricing such securities. Actually, there are at least three pricing
approaches for longevity-linked securities: the Wang transform, the instantaneous Sharpe ratio and
the risk-neutral approach.
The first one is the distortion approach based on the Wang transform Wang (2002) providing
a distortion operator that transforms the death probability distribution to generate risk-adjusted
death probabilities discounted by risk-free interest rates (e.g., see Lin and Cox (2005)). The Wang
transform has been criticized by many authors (see, e.g., Siu-Hang Li and Cheuk-Yin Ng (2011);
Bauer et al. (2010)) because it is not a linear functional and, therefore, yields arbitrage opportunities
that do not lead to a price consistent with the arbitrage-free price. Moreover, as pointed out by
Cairns et al. (2006b), it is not clear “how different transforms for different cohorts and terms to maturity
relate to one another and form a coherent whole”. All of the aforementioned authors conclude that
the Wang distortion approach does not provide a universal framework for pricing longevity-linked
securities and is not a suitable choice in a framework with multiple cohorts.
As briefly described in the Introduction, the second approach applies the Sharpe ratio rule
assuming that the risk premium required by investors to take on longevity risk is equal to the Sharpe
ratio for other undiversifiable financial instruments Milevsky et al. (2005). This approach corresponds
to a change of the probability measure from the real-world measure to a risk-adjusted measure
provided by a constant market price of risk Bauer et al. (2010). As mentioned in the Introduction,
Milevsky et al. (2006) propose for the longevity market a 0.25 level of the Sharpe ratio according to stock
market data. However, Bauer et al. (2010) stated that “empirical studies show that the risk premium
for stocks is considerably higher than for other securities”. The Sharpe ratio can be alternatively
calibrated to a suitable annuity quote, but again, the question relies on the adequacy of the annuity
market to price longevity-linked securities. In this regard, it should be kept in mind that the annuity
provider, in addition to longevity risk, is also subject to other sources of risk, and the resulting risk
premium should be greater than the risk premium for a longevity-linked security.
The third approach consists of adapting the risk-neutral pricing framework developed for
interest-rate derivatives to longevity-linked securities (for example, see Dahl (2004); Cairns et al. (2006a);
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Biffis et al. (2010)). As pointed out by Barrieau et al. Barrieu and Loubergé (2013) “the main underlying
assumption of this approach is that it is possible to replicate cash flows of a given transaction dynamically
using basic traded securities in a highly liquid market”. Therefore, the application of a risk-neutral
approach requires a highly liquid underlying market that is necessary to build a replicating strategy.
Nevertheless, the longevity market at present is far from being liquid, and the specification of the
risk-neutral measure is difficult due to the limited data on the market price of longevity risk.
Our model allows estimating the maximum market price of longevity risk from the information
enclosed in the RM calculated with the Solvency II standard formula. Therefore, it allows applying
the risk-neutral approach that can be generally considered the most adequate methodology
because it is suited for multiple cohorts and ages; unlike the Sharpe ratio approach, it is able to
capture the dependence between different cohorts Meyricke and Sherris (2014) and, unlike, the
Wang transform, provides a uniquely-defined price and then a universal framework for pricing
longevity-linked securities.
We define a risk-neutral probability measure Q that is equivalent to the current real-world measure
P, and we assume that the interest rate is independent of the mortality rate. We set pi in such a way
that the S-forward value is zero at the inception date: we are assuming that the market values of the
fixed and floating legs are equal. Therefore, the following condition holds:
S-forward value =
[
EQ (lx+T,T)− (1+ pi) · EP (lx+T,T)
]
d(0, T) = 0 (2)
where d(0, T) is the price at Time 0 of a zero-coupon bond paying a fixed amount of one at time T.
From Equations (1) and (2), we can find the fixed proportional S-forward premium, pi, as follows:
pi =
EQ (T px,0)
T pˆx,0
− 1 . (3)
Note that (1+ pi) can be written as eδT , where δ is the spread required by the floating leg payer
expressed as a continuously compounding rate. Hence, δ is given by:
δ = ln
[
EQ (T px,0)
T pˆx,0
]
1
T
. (4)
3. Pricing S-Forwards via the Risk Margin
Under the Solvency II project, the market value of the liabilities related to unhedgeable risks is set
equal to the sum of its best estimate (BE) and a risk margin (RM), representing a risk adjustment of
the BE. The RM is then determined by a cost-of-capital (CoC) approach, i.e., by the cost of providing
an amount of capital equal to the SCR necessary to fulfill the insurance obligations over time.
In the definition proposed by Solvency II, the SCR at Time 0 is the capital required to cover, with
99.5% probability, the unexpected losses on a one-year time horizon. The CoC rate represents the
average spread over the risk-free rate, which the market requires as earning on insurance companies’
equity. As observed by Zhou and Li (2013), the profit margin, which an insurance company taking
on risk must include in its insurance premiums, should typically be no less than the risk margin.
However, an exact computation of the RM would require the determination of SCRt, conditional on
the mortality evolution up to time t (see Christiansen and Niemeyer (2014) for the SCR definitions for
future points in time). For practical purposes, the computation of SCR future values is too complex,
so that simplifications are needed Börger (2010). In the EIOPA Guidelines on the valuation of technical
provisions EIOPA (2014b), some approximations are listed (see Guidelines 62). In the following, we
will consider the approximation of the SCRt by assuming a mortality evolution up to time t according
to its best estimate. In the formula, the RM at time t is defined as:
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RMt = 6%
T−1
∑
i=t
SCRi d(t, i + 1) , (5)
where the CoC rate is set to 6% as fixed in the current Solvency II standard formula, the SCRi is the SCR
for year i and d(t, i + 1) is the discount factor calculated with the risk-free interest rate term structure.
Solvency II provides several methods to calculate the SCR: full internal model, standard formula
and partial internal model, standard formula with undertaking-specific parameters, standard formula
simplification. In the following, we will consider the standard formula, as well as two partial internal
models. The estimates derived from the partial internal models are compatible with the overall
calibration objectives for the standard formula (i.e., a value at risk with a 99.5% confidence level over
a one-year time horizon) as required by Solvency II.
(a) SCR under the standard formula:
The Solvency II project suggests a standard formula to compute the above-defined SCR. If we just
consider the SCR related to longevity risk and assume no other risk exists, the SCR required at t
for an insurance company with a portfolio of pure endowments is equal to:
SCRshockt = ∆BOFt
∣∣longevity shock = Vshockt − Vˆt , (6)
where ∆BOFt
∣∣longevity shock = BOFt − BOFshockt denotes the change in the value of its basic
own funds at time t due to a longevity shock; Vshockt is the value of the technical provisions after
experiencing a longevity shock; and Vˆt is the BE of the technical provisions. The longevity shock
in the standard formula is a permanent reduction by 20% of the BE of the mortality rates at each
age EIOPA (2014a).
(b) SCR under the VaR measure:
Instead of the standard formula that sets a deterministic longevity shock, a more appropriate
model to capture the insurer risk can be based on the calculation of ∆BOF in a stochastic setting
as a function of value at risk (VaR) of liabilities given a fixed confidence level. In general form, the
VaR measures the potential loss in value of a risky asset or liability over a defined time horizon
for a given confidence level, say 99.5% (i.e., with a 0.5% ruin probability). The SCRVaRt can be
defined as:
SCRVaRt = ∆BOFt
∣∣longevity VaR = VVaRt − Vˆt , (7)
where VVaRt = VaR99.5%(Vt) is the quantiles at the 99.5% confidence level of technical provisions.
(c) SCR under the stressed-trend approach:
As longevity risk arises from the uncertainty in changes of the long-term mortality trend,
Richards et al. (2013) argue that a stressed-trend approach is the most appropriate way to
investigate longevity trend risk. This trend is the result of an accumulation of small changes over
many years; therefore, technical provisions should be calculated via a long-term stress projection
from a stochastic mortality model, under a stressed-trend approach. There has been plenty of
feedback from QIS4 and QIS5 participants on the adequacy of the one-off shock approach for
longevity risk recommended by the standard formula. “As the current shock was only a shock
on the level, it failed to adequately take into account trend risk: undertakings felt a stress on the
future improvement rates would be more appropriate” EIOPA (2011). We define the SCR under
the stressed-trend approach, SCRstresst , as:
SCRstresst = ∆BOFt
∣∣longevity stressed-trend = Vstresst − Vˆt , (8)
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where Vstresst is the technical provision calculated by the stressed-trend mortality projection
obtained by deducting the Φ−1(99.5%) projection standard error from the central projection,
where Φ is the cumulative distribution function of a normal (0,1) (see Richards et al. (2013) for
further details). The projection standard error here encloses parameter risk and not process risk,
i.e., the risk arising from the variability of the time processes used to represent the biometric
trends. It is usually denoted as the risk of random fluctuations and is a diversifiable risk, because
it decreases, in relative terms, by increasing the portfolio size.
Observe that, while the standard formula is based on a deterministic approach, the computation of
the SCR for longevity risk via the VaR approach and the stressed-trend approach requires a stochastic
mortality model.
Under a given approach (a, b or c) and assuming a mortality evolution up to time t according to
its best estimate, the SCRt for a portfolio of pure endowments is given by:
SCRt = V
′
t − Vˆt = lx,0( t pˆx,0 ·T−t p′x,t −T pˆx,0) d(t, T) . (9)
where T pˆx,0 is the BE of survival probabilities and T−t p′x,t are the survival probabilities at time
t calculated according to a defined approach (a, b or c):
T−t p′x,t =

T−t pshockx,t (a)
T−t pVaRx,t (b)
T−t pstressx,t (c)
(10)
where T−t pVaRx,t are the quantiles at the 99.5% confidence level of the stochastic survival probabilities
that an individual alive at t at age x+ t will be alive at T at age x+ T and T−t pstressx,t are the stressed-trend
survival probabilities.
Assuming that an insurer is completely hedged against longevity risk, by assumption the only risk
source, there is no need for the company to set any solvency capital aside. Both the SCR and the RM
reduce to zero. Reasonably, we can assume that an insurer might be interested in securitizing his/her
longevity risk if the transaction price is lower or equal to the present value of the future CoC required
upon longevity risk. Following this point of view, the RM can be considered as the “maximum price”
that an insurance company would pay for longevity risk securitization (see Börger (2010)). As argued
in the Introduction, if we take into account the counterparty default risk, we should include the RM
for such a risk. In this case, the “maximum price” should be less.
Consider an insurance company entering an S-forward with maturity T. The SCR at time t after
the hedging is equal to:
SCRSt = (lx,0 − lSx,0)t pˆx,0(T−t p′x,t −T−t pˆx,t) · d(t, T) , (11)
where lx,0 and lSx,0 are the survivors in the portfolio of pure endowments and those underlying
the S-forward, respectively. Note that if these two quantities coincide, lx,0 = lSx,0, then SCR
S
t = 0.
Substituting Equations (9) and (11) in Equation (5), we derive the following values of the RM in t = 0
before and after the hedging, respectively:
RM0 = 6%
T−1
∑
i=0
SCRi · d(0, i + 1) = 6% · lx,0 · d(0, T)·
·
T−1
∑
i=0
i pˆx,0(T−i p′x,i −T−i pˆx,i)d(i, i + 1) ,
(12)
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RMS0 = 6%
T−1
∑
i=0
SCRSi · d(0, i + 1) = 6% · (lx,0 − lSx,0) · d(0, T)·
·
T−1
∑
i=0
i pˆx,0(T−i p′x,i −T−i pˆx,i)d(i, i + 1) .
(13)
The difference between the RM before and after the longevity hedging (∆RM0 = RM0 − RMS0 )
provides a measure of the amount of RM saved by the insurer hedging the longevity risk through an
S-forward:
∆RM0 = 6% · lSx,0 · d(0, T)
T−1
∑
i=0
i pˆx,0(T−i p′x,i −T−i pˆx,i)d(i, i + 1) . (14)
Clearly, when lx,0 = lSx,0, the RM saved by the insurer exactly matches the RM for longevity risk
(see Equation (12)). We assume that such savings corresponds to the maximum premium that an
insurer would pay for hedging longevity risk. This leads to:
∆RM0 ≥ pi · lˆSx+T,T · d(0, T). (15)
where lˆSx+T,T = l
S
x,0 ·T pˆx,0. From Equations (14) and (15), we can obtain the “maximum price” pimax for
the S-forward fixed payer (or the corresponding spread required by the floating leg payer, δmax):
pimax = eδ
maxT − 1 =
= 6%
(
∑T−1i=0 i pˆx,0 ·T−i p′x,i · d(i, i + 1)
T pˆx,0
−
T−1
∑
i=0
d(i, i + 1)
)
.
(16)
δmax = ln
[
6% ∑T−1i=0 i pˆx,0 ·T−i p′x,i · d(i, i + 1) +T pˆx,0(1− 6%∑T−1i=0 d(i, i + 1))
T pˆx,0
]
1
T
. (17)
This result is valid for basic instruments with a single maturity, as an S-forward. At present, the
market of S-forwards is far from being developed. Therefore, pimax (or the spread δmax), calculated
through the RM, can be used for pricing these derivatives. Thus, the hedger should not be interested
in entering into a transaction if the price is higher than that calculated with this approach. Besides,
the pimax calculated on different maturities can be used to find the “maximum price” of vanilla
survivor swaps.
3.1. The Market Price of Longevity Risk
Given a stochastic mortality model with n factors, the dynamics of the model under the
risk-adjusted pricing measure Q depends on a vector of the market price of longevity risk
λ = (λ1,λ2, ...,λn), associated with the n factors. Assuming that pi = pimax and reminding
about the relation between pi and the ratio between risk-neutral and real-world survival probabilities
(see Equation (3)), we obtain a “maximum” value for EQ (T px,0):
EmaxQ (T px,0) = (1+ pi
max)T pˆx,0 = 6%
T−1
∑
i=0
i pˆx,0 ·T−i p′x,i · d(i, i + 1)+
+T pˆx,0
[
1− 6%
T−1
∑
i=0
d(i, i + 1)
]
.
(18)
Now, we can find the market price of longevity risk λ minimizing the squared errors between the
maximum value of the risk-neutral survival probabilities calculated via the RM approach, EmaxQ (T px,0),
and the risk-neutral survival probabilities depending on the mortality, model, EQ(λ) (T px,0), so that:
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λ = arg min
λ
m
∑
j=1
[
EmaxQ
(
Tj pxj ,0
)
− EQ(λ)
(
Tj pxj ,0
)]2
. (19)
where m is the number of S-forwards the model is calibrated to and Tj and xj are respectively the
maturity and the age at issue of the reference population of the j-th S-forward.
Note that the values of λ could be used to find the “maximum price” of more complex
longevity-linked securities. In the next section, we describe the mortality model we use in the paper.
4. The Mortality Model
We define Dx,t as the deaths occurring during year t at age x, assumed to follow a Poisson
distribution, Ex,t the exposed-to-risk aged x during year t so that the central death rate at age x and
time t are estimated as mx,t =
Dx,t
Ex,t . Let qx,t be the probability to die in year t for an individual aged
x and px,t = 1− qx,t the corresponding survival probability. We make the usual assumption that
the force of mortality remains constant over each year of integer age and over each calendar year.
This implies that the relationship between qx,t and mx,t is given by qx,t = 1− e−mx,t .
Various stochastic mortality models have been set forth in recent years. We select the model
among seven stochastic models that best fits our data according to the Bayes information criterion
(BIC), an objective model selection criterion based on the statistical quality of fit 1.The seven models
we compared are taken from the paper of Cairns et al. (2009) and include the Lee–Carter model (LC),
its extension proposed by Renshaw and Haberman (RH), the age-period-cohort model introduced by
Currie, the Cairns–Blake–Dowd model (CBD) and three extensions that add a cohort effect, a quadratic
term to the age effect and a different form of the cohort effect, respectively. We fit the seven models
to the mortality data of the Italian population downloaded from the Human Mortality Database
HMD (2010), related to the age range 60–90 and the period 1974–2007 for males. Data start from year
1974 as the first year of available time series on mortality tables, annually processed by the Italian
National Institute of Statistics (ISTAT) according to a uniform methodology. The fitting results are
shown in Table 1 where the extension of the Cairns–Blake–Dowd model including a cohort component,
here indicated as the CBD-1, is characterized by the highest value of the BIC statistic. In order to ensure
completeness, we included the corresponding maximum log-likelihood (MLL) estimates for all of the
analyzed models. The CBD-1 model is described by the following equation:
logit(qx,t) = ln
(
qx,t
1− qx,t
)
= k(1)t + k
(2)
t (x− x¯) + γ(3)c . (20)
where x¯ is the average of the ages used in the dataset, k(1)t and k
(2)
t reflect period-related effects
and γ(3)c represents the cohort-related effect, with c = t− x. To avoid any identifiability problems,
two constraints were introduced: ∑c∈C γ
(3)
c = 0 and ∑c∈C c γ
(3)
c = 0, where C is the set of cohort years
of birth that have been included in the analysis (1884–1947).
1 The BIC is defined as: BIC = l(ρˆ)− 0.5Kln(N), where l(ρˆ) is the log likelihood function, ρ is the set of parameters to be
estimated with the likelihood function, ρˆ is the maximum likelihood estimate of the parameters vector, N is the number of
observations and K the effective number of estimated parameters. The log likelihood function of the model is defined as:
l(ρ; D, E) = ∑x,t {Dx,t ln [Ex,tmx,t(ρ)]− Ex,tmx,t − ln(Dx,t !)}.
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Table 1. Maximum log-likelihood estimates, BIC statistic and rank for each model calculated on
mortality rates of Italian males, ages 60–90, years 1974–2007.
Model MML BIC Rank (MLL) Rank (BIC)
LC −9823 −10149 7 7
RH −6105 −6754 1 4
Currie APC −7049 −7486 5 5
CBD −9691 −9927 6 6
CBD-1 −6230 −6681 3 1
CBD-2 −6122 −6688 2 2
CBD-3 −6250 −6709 4 3
In Figure 2 we show the maximum-likelihood estimates of k(1)t , k
(2)
t and γ
(3)
c . We can see
a distinctive cohort effect in the parameter γ(3)c , showing that cohort mortality is rising at a higher rate
for males born after 1920. In the estimation of the cohort effect, we excluded cohorts for which there
were less than five observations: cohorts’ birth in 1884–1887 and 1944–1947.
(a) (b) (c)
Figure 2. Estimated parameters of the CBD-1 model, Italian male population, ages 60–90, years
1974–2007. (a) Parameter k(1)t ; (b) Parameter k
(2)
t ; (c) Parameter γ
(3)
c .
4.1. Mortality Projections
In order to make forecasts of the CBD-1 model, we select a multivariate ARIMA model for
the three processes of the estimated parameters k(1)t , k
(2)
t and γ
(3)
c . In more general notation, the
multivariate ARIMA model can be described as:
Ks+1 = Ks + φ (Ks − Ks−1) + µ+ C Zs+1 (21)
where Ks is the vector of parameters k(1), k(2) and γ(3) at step s, where s indicates the time t or the
cohort c according to the case; φ is the vector of parameters of the autoregressive part of the model; µ
is a 3 × 1 vector of the drifts of the model; C is a 3 × 3 constant upper triangular matrix so that CC′ is
the covariance matrix; and Z is a 3 × 1 vector of standard normal random variables.
Balancing between the best selected ARIMA models fitting the parameters 2 and the desire to
deal with a simple model, we chose an ARIMA(0,1,0) to describe the first two parameters, k(1) and k(2),
and an ARIMA(1,1,0) for the cohort parameter γ(3)c . We assume the existence of correlation between
2 The goodness of fit is assessed through both the maximum log-likelihood function and Akaike’s information criterion
AIC = 2l + 2K, where l is the log likelihood function and K the effective number of estimated parameters.
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parameter k(1)t and k
(2)
t , while we adopt the usual assumption that γ
(3)
c is independent of the others.
Results of the fitting procedure on Italian data are reported in Table 2.
Table 2. Fitted parameters of the ARIMA models.
Parameter ARIMA σ2 µ φ
k(1) (0,1,0) 0.000783 −0.020394 0
k(2) (0,1,0) 0.000001 0.001015 0
γ(3) (1,1,0) 0.000871 0.002610 −0.644393
The fitted matrix C is as follows:
C =
0.027975 0 00.000476 0.001094 0
0 0 0.029513
.
Note that under the stressed-trend approach, the mortality model is given by logitstress(qx,t) =
logit(q̂x,t)− σx,t ·Φ−1(99.5%), where q̂x,t is the mortality rate from the central projection and σx,t is the
volatility arising from the uncertainty originating from the ARIMA parameters estimate.
4.2. The Risk-Neutral Mortality Model
In the following, we specify the risk-neutral approach to the mortality model described in the
previous subsection, which so far was defined under the real-world probability measure P. For the
multivariate ARIMA model specified by Equation (21) under the risk-neutral measure Q, we propose:
Ks+1 = Ks + φ(Ks − Ks−1) + µ+ C(ZQs+1 − λ) (22)
where the vector λ = (λ1,λ2,λ3) is the market price of longevity risk associated with processes Z(1),
Z(2) and Z(3) under the measure Q, respectively. Following Cairns et al. (2006a), in the absence of
complete market price data, we assume that λ is constant over time.
Vector λ should be calibrated on the market price of longevity-linked securities when available.
The market of longevity-linked securities being incomplete, it is not always possible to find real
market data. Following the approach proposed in Section 3, we find the market price of longevity risk,
λ = (λ1,λ2,λ3) according to Equation (19). To solve the minimization problem in such an equation,
we have used the optim() function in the statistical computing software R (R Core Team (2015)).
The market price of longevity risk affects the logit of death probabilities under the risk-neutral
measure in the following way (see Figure 3):
• λ1: positive values produce a downward shift and a lower slope of the curve (the latter effect is
due to the presence of a positive correlation between parameters k1 and k2);
• λ2: positive values produce a lower slope of the curve and a rotation around the point
(x¯, logit(qx¯));
• λ3: if we consider cohort data, positive values produce a downward shift of the curve only for
future cohorts, while in the case of cross-sectional data, positive values increase the slope of the
curve for future cohorts, while the slope does not change for historical cohorts.
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(a) (b) (c)
Figure 3. Logit of projected death probabilities (year 2023) under the real-world probability measure
and risk-neutral probability measure with different λ values. (a) λ = (1, 0, 0); (b) λ = (0, 1, 0);
(c) λ = (0, 0, 1).
5. Numerical Results
In this section, we show the results of the numerical application of our model for the Italian
population. Tables 3–5 show the values of δmax evaluated in the year 2008 for the cohorts of individuals
aged 65, 70, 75, 80, 85 and for different maturities T, according to the three specifications of the SCR.
Table 3. Values of δmax for different cohorts and maturities. Standard formula approach.
Age: 65 70 75 80 85
T δmax : standard formula approach (a)
5 0.000533 0.000903 0.001652 0.003176 0.00568
10 0.001306 0.002337 0.004465 0.008911 -
15 0.003161 0.005533 0.010492 - -
20 0.006731 0.011762 - - -
25 0.013637 - - - -
Table 4. Values of δmax for different cohorts and maturities. VaR approach.
Age: 65 70 75 80 85
T δmax: VaR approach (b)
5 0.000261 0.000479 0.000984 0.002044 0.003711
10 0.000969 0.001857 0.003860 0.007883 -
15 0.003080 0.005889 0.011727 - -
20 0.008129 0.014827 - - -
25 0.018580 - - - -
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Table 5. Values of δmax for different cohorts and maturities. Stressed-trend approach.
Age: 65 70 75 80 85
T δmax: Stressed-trend approach (c)
5 0.000456 0.000787 0.001475 0.002891 0.005216
10 0.001593 0.002885 0.005607 0.011253 -
15 0.004670 0.008326 0.015965 - -
20 0.011347 0.020044 - - -
25 0.024735 - - - -
Values of δmax do not increase linearly with the S-forward maturity (see Figure 4 for the VaR
approach; plots for other approaches are similar) as a natural consequence of the increasing uncertainty
of survival probabilities for longer time horizons. Moreover, δmax increases with the starting age of the
underlying cohort due to the increasing uncertainty of survival probabilities for older ages. This means
that hedgers are disposed to accept a higher spread when the cohort is older or the maturity is longer.
Figure 4. Values of δmax for the cohorts aged 65–85 in 2008 and all of the maturities. Red lines: cohorts
aged 65, 70, 75, 80 and 85.
To better understand the differences in the maximum price δmax among the considered approaches,
in Figure 5, we plot the survival probabilities, T px,t, implied in the calculation for five cohorts (aged 65,
70, 75, 80, 85 in year 2008). For example, if we consider the cohort born in 1933, we can observe that
the five-year survival probability under the shock approach is higher than the corresponding survival
probability calculated using VaR and stress-trend approaches. This causes a higher δmax in the shock
approach for S-forwards with a five-year maturity compared to the other approaches. The opposite
scenario occurs if we look at the 15-year survival probability.
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(a) Cohort 1943 (b) Cohort 1938
(c) Cohort 1933 (d) Cohort 1928
(e) Cohort 1923
Figure 5. Values of T pˆx,0, T pshockx,0 and T p
VaR
x,0 for different cohorts.
As described in Section 3.1, we obtain the vector of the market price of longevity risk λ minimizing
the squared errors between the risk-neutral survival probabilities and the corresponding value
calculated via the RM approach (see Equation (19)). The λ vector is calibrated on the maximum
S-forward prices evaluated in 2008 considering the set of ages 65–85 and the maturities from 5–25 years.
Results are given in Table 6.
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Table 6. Market price of longevity risk λ.
Parameters λ
(a) Standard formula (b) VaR (c) Stressed-trend
k(1) 0.421670 0.410675 0.652299
k(2) 0.009506 0.352785 0.294197
γ(3) −0.198082 −0.207165 −0.501635
The heat map of the relative percentage error (RPE),
EmaxQ
(
Tj
pxj ,0
)
−EQ(λ)
(
Tj
pxj ,0
)
EmaxQ
(
Tj
pxj ,0
) , is plotted in Figure 6.
It helps to identify the difference between the risk-neutral probabilities by age (vertical lines) and
maturity (horizontal lines) with light grey areas indicating positive values, while dark grey areas show
negative values. In all of the graphs of Figure 6, the most negative values are found for older ages
and smaller maturities, while the most positive values are found for the younger ages and larger
maturity. This implies that the model underestimates the risk-neutral probabilities for contracts with
smaller maturities and older cohorts, and conversely, it overestimates the risk-neutral probabilities for
contracts with larger maturities and younger cohorts.
(a) Standard formula approach (b) VaR approach
(c) Stressed-trend approach
Figure 6. Values of
EmaxQ
(
Tj pxj ,0
)
−EQ(λ)
(
Tj pxj ,0
)
EmaxQ
(
Tj pxj ,0
) according to different approaches.
We also analyzed the behavior of pimax and λ when the CoC rate varies in the range of 4–8%
for each of the approaches here considered. Obviously, pimax values show an increase/decrease
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proportional to the increase/decrease of the CoC rate (see Equation (16)). From the pimax values,
we then estimated the λ vector satisfying Equation (19) (results are shown in Figure 7).
(a) λ1 (b) λ2 (c) λ3
Figure 7. Values of λ = (λ1,λ2,λ3) according to different approaches and different cost-of-capital
(CoC) (4%, 6%, 8%).
In Figure 8, we study the impact of different CoC rates on the logit transform of death probabilities
(evaluated in 2008) and on the logit transform of projected death probabilities (evaluated in year 2023)
under both the real-world and risk-neutral probability measure. Results show that an increase in the
CoC rate produces, within the standard formula approach, a downward shift of the logit(qx,t) under
the risk-neutral measure. This shift is mainly obtained by an increase of λ1; however, a change in
λ1 also produces a rotation around the point (x¯, logit(qx¯)) that is compensated by a reduction of λ2.
Under the standard formula approach, λ3 has minor changes. A similar behavior, but at a greater level,
is observed under the stressed-trend approach. Conversely, under the VaR approach, an increase of the
CoC rate involves a downward shift of the logit(qx,t) under the risk-neutral measure accompanied by
a decrease in the slope for cohorts prior to 1943 (age less than 80 years in 2023). In these cases, λ3 has
negative values, decreasing along with the CoC rates.
(a) (b) (c)
Figure 8. Logit transform of projected death probabilities (year 2023) under the real-world probability
measure and risk-neutral probability measure with different CoC values. (a) Standard formula
approach; (b) VaR approach; (c) Stressed-trend approach.
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5.1. q-Forward Pricing
As mentioned above, the market price of longevity risk provided by our model could be used
to price other longevity-linked securities. Up to now, a wide range of longevity-linked securities has
been proposed on the market, e.g., longevity bonds, longevity or survivor swaps and q-forwards.
Among these, q-forwards have several advantages: they are based on standardized indices reflecting
the experience of a large population, and they are less difficult to price, less expensive and more liquid.
For these reasons, we decided to focus our analysis on q-forwards. A q-forward is a zero-coupon swap
that involves the exchange at maturity date of a fixed amount for a random amount that is proportional
to a mortality index for the reference population at maturity. The fixed payment is proportional to the
forward mortality rate for the reference population and is set so that the q-forward value is zero at
inception (see Coughlan et al. (2007) for further details on the mechanism of q-forwards). The payoff
of q-forwards usually depends on the average mortality rate for age-buckets of five or 10 years.
In our model, we obtain the values of q-forwards as the risk-neutral expectation, EQ(qx,T) while
their prices are usually calculated according to the Sharpe ratio approach (see, e.g., the LifeMetrics
technical document Coughlan et al. (2007)), as follows:
q fx,T = (1− SR · T · σx)qex,T (23)
where T is the time to maturity, SR is the required annualized Sharpe ratio and σx = sd
(
∆qx,T
qx,T
)
is the
historical standard deviation of changes in the mortality rate.
We consider a set of three q-forwards for age-buckets of five years, from age 65 up to age 79 with
different maturities. Results obtained with our model are shown in Figure 9 compared with the
expected mortality rate qex,T . q-forwards values calculated under both the standard formula and VaR
approaches are quite similar, while they are lower under the stressed-trend approach, consistent with
the results in Figure 5.
(a) Age 65-69 (b) Age 70-74 (c) Age 75-79
Figure 9. Q-forward prices by different age groups.
Now, we can estimate the implied maximum Sharpe ratio, SR = 1Tσx
(
1− q
f
x,T
qex,T
)
, that an annuity
provider should be willing to pay to hedge longevity risk from the q-forward prices reported in Figure 9.
The Sharpe ratio values for the set of three q-forwards with a 10-year maturity are reported in Table 7.
Results differ from one approach to the other, but the standard formula and VaR approaches produce
values that are quite similar to 0.25, usually suggested in the literature (see, e.g., Milevsky et al. (2006);
Loeys et al. (2007)).
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Table 7. Sharpe ratio.
Age Group Standard Formula VaR Stress-Trend
65–69 0.21 0.21 0.31
70–74 0.23 0.29 0.37
75–79 0.23 0.32 0.39
6. Conclusions
In this paper, we have investigated the possibility to price S-forwards using the information
enclosed in the risk margin and the standard formula under the Solvency II project. Our approach
provides estimates of the “maximum price” that the fixed payer is disposed to pay for hedging
longevity risk. If the required S-forward price were higher, the annuity provider would have the
convenience of keeping longevity risk. The “maximum price” is calculated under the Solvency II
standard formula and two partial internal models (one based on the VaR and the other one on the
stressed-trend approach) for different ages and maturities, as well as for different levels of CoC rate.
Once a mortality projection model is defined under the real-world probability measure,
we calibrate the upper limit of market price of longevity risk, λ, associated with the risk-neutral
mortality model. In the same pricing framework, λ values can be used to find the “maximum price”
of other longevity-linked securities. Specifically, we price q-forwards, and we calibrate the implied
maximum Sharpe ratio that an annuity provider should be willing to pay to hedge longevity risk.
The prices provided by our model seem consistent with those obtained by other commonly-used
approaches (e.g., the Sharpe ratio) and offer a point of reference for insurance companies or pension
funds in defining longevity risk hedging policies through longevity-linked securities. In fact, these
prices represent the threshold above which it is not convenient to use these hedging tools, and risk
retention requiring an appropriate level of solvency capital becomes preferable.
In the numerical example here provided, only the Cairns–Blake–Dowd (with cohort effect)
mortality projection model is used. It would be interesting to analyze the effects of different mortality
models on the market price of longevity risk, taking into consideration the model risk in the pricing.
This aspect will be object of future research.
One shall notice that the approach suggested in this paper depends on two fundamental
assumptions. First of all, we adopt the CoC method to calculate RM, while one might consider other
methods and assess whether the results obtained were similar to the CoC method both numerically
and in terms of the considered variables. Secondly, we assume that all insurance companies accept
the same market price of longevity risk implicit in the RM calculation under Solvency II. However,
diversification effects, strategic reasons and attitude toward risk could induce the insurer to accept
a different market price of longevity risk (see Börger (2010)). Moreover, we have not considered
the counterparty default risk that would increase the costs of longevity-linked securities and require
a specific capital charge for the insurer. The effect of this risk on the risk margin and the maximum
price of longevity risk should be the object of further research.
Finally, it should be kept in mind that the proposed methodology highly depends on the individual
situation of the insurance company and that the paper aims to establish a maximum price for the market
of longevity-linked securities, tailored to the insurer’s specific portfolio. Although our approach has
some limitations, it has the advantage of working in the known and possibly standardized framework
of Solvency II, and the RM can be considered a possible tool to estimate a maximum value for the
market price of longevity risk.
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